RT Journal Article
T1 Stroke prevention in patients with type 2 diabetes or prediabetes. Recommendations from the Cerebrovascular Diseases Study Group, Spanish Society of Neurology.
T2 Prevención de ictus en pacientes con diabetes mellitus tipo 2 o prediabetes. Recomendaciones del Grupo de Estudio de Enfermedades Cerebrovasculares de la Sociedad Española de Neurología.
A1 Fuentes, B
A1 Amaro, S
A1 Alonso de Leciñana, M
A1 Arenillas, J F
A1 Ayo-Martín, O
A1 Castellanos, M
A1 Freijo, M
A1 García-Pastor, A
A1 Gomis, M
A1 Gómez Choco, M
A1 López-Cancio, E
A1 Martínez Sánchez, P
A1 Morales, A
A1 Palacio-Portilla, E J
A1 Rodríguez-Yáñez, M
A1 Roquer, J
A1 Segura, T
A1 Serena, J
A1 Vivancos-Mora, J
A1 Comité ad hoc del Grupo de Estudio de Enfermedades Cerebrovasculares de la Sociedad Española de Neurología, 
K1 Diabetes tipo 2
K1 Ictus
K1 Insulin resistance
K1 Prediabetes
K1 Prevención
K1 Prevention
K1 Resistencia a la insulina
K1 Stroke
K1 Type 2 diabetes
AB To update the Spanish Society of Neurology's guidelines for stroke prevention in patients with type 2 diabetes or prediabetes, analysing the available evidence on the effect of metabolic control and the potential benefit of antidiabetic drugs with known vascular benefits in addition to conventional antidiabetic treatments in stroke prevention. PICO-type questions (Patient, Intervention, Comparison, Outcome) were developed to identify practical issues in the management of stroke patients and to establish specific recommendations for each of them. Subsequently, we conducted systematic reviews of the PubMed database and selected those randomised clinical trials evaluating stroke as an independent variable (primary or secondary). Finally, for each of the PICO questions we developed a meta-analysis to support the final recommendations. While there is no evidence that metabolic control reduces the risk of stroke, some families of antidiabetic drugs with vascular benefits have been shown to reduce these effects when added to conventional treatments, both in the field of primary prevention in patients presenting type 2 diabetes and high vascular risk or established atherosclerosis (GLP-1 agonists) and in secondary stroke prevention in patients with type 2 diabetes or prediabetes (pioglitazone).
YR 2020
FD 2020-09-24
LK http://hdl.handle.net/10668/16324
UL http://hdl.handle.net/10668/16324
LA en
LA es
DS RISalud
RD Apr 5, 2025